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2880for this graph was to take the same approach used previously by our
group (1) to address the frequently raised question of whether
lifespan gain really does expand progressively with time, even
though many commentators simply state that “one has to implant x
devices to obtain a beneﬁt” without specifying a time window.
Figure 2 shows that no single value is correct for all time windows.
Nothing from Figure 2 is used elsewhere in our paper.
For the lifespan gain calculations in the main paper, we used
hazard ratios published by the trialists themselves, because these
came from the entire trial period, which maximized the information
extracted from the data. All 5 trials provided a hazard ratio, but not
all provided the 95% conﬁdence interval. We could not, therefore,
calculate the ideal inverse-variance–weighted average using the
reciprocal of the conﬁdence interval width and instead used an
unweighted average of the 5 hazard ratios. Lifespan gains were
calculated using a life table with annual deaths calculated from
2 competing hazards. One hazard was amenable to reduction by
cardiac resynchronization therapy device implantation; the other
was not and instead increased annually by a scale factor of 1.1.
The second inquiry was how the Gompertz method was used to
calculate lifespan gain in the post-trial period. We did not attempt
to ﬁt Kaplan-Meier survival curves to the Gompertz equation
because, as Dr. Messori and colleagues rightly point out, this is
mathematically and statistically complex. It would additionally be
unwise to attempt to extract from the trial data the Gompertz
coefﬁcient, which quantiﬁes rising mortality hazard with aging
(equivalent to longer after randomization). First, trials typically do
not report survival for sufﬁciently long periods for curves to show
appreciable convexity (mortality acceleration), that is, the Gom-
pertz coefﬁcient has not yet manifested. Second, because of stag-
gered enrollment, at later times from randomization there are fewer
patients being followed, so random noise dominates the Kaplan-
Meier curves, which further imperils any attempt to extract the
Gompertz coefﬁcient. We therefore set the Gompertz exponent eb
at b¼0.095 per year to scale up the hazard of non–cardiac
resynchronization therapy–preventable mortality by a factor of 1.1
every year, based on the U.S. national census data of 2003.
We thank Dr. Messori and colleagues for helping ensure our
methods are clear and, as always, welcome any further questions via
the Journal or directly.*Judith A. Finegold, MBBS
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Consider How to Balance
Cardiorenometabolic Beneﬁts
and Risks of Statins?Two recent papers demonstrated that atorvastatin 80 mg versus
10 mg reduced periodontal (1) and atherosclerotic plaque (2)
inﬂammation. These studies may explain the results of a study
that showed that atorvastatin 80 mg versus 10 mg provided sig-
niﬁcant cardiovascular beneﬁt in patients with stable coronary heart
disease (3). However, we should keep in mind that these beneﬁts
occurred with a greater incidence of elevated aminotransferase
levels (1.2% vs. 0.2%, p < 0.001) and greater rates of discontinu-
ation because of treatment-related adverse events (7.2% vs. 5.3%,
p < 0.001) and deaths of noncardiovascular causes (3.2% vs. 2.5%,
p ¼ 0.07) (3).
The adverse effects of statins, such as myopathy and liver
toxicity, are dose dependent; however, whether the unwanted effect
of statins on acute renal failure is dose dependent has not been
investigated, much as the unwanted effect of statins to induce type
2 diabetes mellitus has been neglected over the decade. We ﬁrst
reported that high-dose atorvastatin therapy had greater adverse
effects on glucose homeostasis than low-dose atorvastatin therapy
in hypercholesterolemic patients (4). A recent paper delineated an
association between acute kidney injury and use of high-potency
statins versus low-potency statins (5). In patients without chronic
kidney disease, current users of high-potency statins were 34%
more likely to be hospitalized with acute kidney injury within
120 days after starting treatment. High-potency statin use in
chronic kidney disease did not result in as large an increase in
admission rate. The increased risk of admission remains elevated
for at least 2 years.
Nonetheless, statins are very important to prevent cardiovascular
events in patients with a high or even low risk of vascular disease.
However, we should keep in mind that the long-term adverse
effects of new-onset diabetes mellitus or acute kidney injury may
generate a relative increase in deaths. Although some studies have
demonstrated that high-potency statins are associated with an
increased rate of diagnosis of acute kidney injury in hospital ad-
missions and new-onset diabetes mellitus compared with low-
potency statins, the long-term outcome of these unwanted effects
versus cardiovascular outcome is questionable and should be
investigated.*Kwang Kon Koh, MD, PhD
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Consider How to Balance
Cardiorenometabolic Beneﬁts
and Risks of Statins?We thank Dr. Koh for his thoughtful comments regarding our
paper (1). There is little doubt that statins are one of the most
effective drug classes of our generation. The mechanisms under-
lying their effectiveness continue to be studied carefully, and there
is growing recognition that their nonlipid (pleiotropic) effects (their
anti-inﬂammatory actions in particular) may impart an important
portion of the beneﬁts of statins to the atherosclerotic milieu. In
support of this concept, we recently observed that the beneﬁcial
impact of atorvastatin on atherosclerotic inﬂammation, as
measured by ﬂuorodeoxyglucose–positron emission tomography/
computed tomography imaging, was not signiﬁcantly related to the
magnitude of low-density lipoprotein reduction (1). Furthermore, a
growing number of studies have highlighted anti-inﬂammatory
beneﬁts of statins that extend beyond atherosclerotic diseases,
including the example raised by Dr. Koh, wherein high-dose
atorvastatin was found to reduce periodontal inﬂammation (2).
Such observations may ultimately pave the way for even broader use
of statins, pending conﬁrmation in clinical endpoint trials. More-
over, the recently published Guideline on the Treatment of Blood
Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in
Adults makes recommendations for statin dosing based more on
risk assessment than on lipid targets (3) and is predicted to increase
the number of Americans who will be treated with statins (4).
Accordingly, the point raised by Dr. Koh is both important and
timely: as we continue to expand the use of statins and contemplate
new indications for them, we should in parallel continue to carefully
study the mechanisms underlying their negative effects, especially
in higher doses. It is hoped that a better understanding of the
mechanisms underlying both the beneﬁts and the untoward effects
of statins will ultimately contribute to the development of novel,
more effective therapies.*Ahmed Tawakol, MD
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of Sickle Cell Disease
Beyond Classiﬁcation Constraints
We read with interest the “Updated Clinical Classiﬁcation of Pul-
monaryHypertension” by Simonneau et al. (1) in a recent issue of the
Journal. We are concerned that although systemic sclerosis, portal
hypertension, schistosomiasis, and chronic hemolysis result in pul-
monary hypertension (PH) that spans several diagnostic groups, the
rules for subgroup inclusion into Group I have not been consistently
applied. On behalf of the American Thoracic Society–sponsored
Clinical Guidelines for the Diagnosis and Treatment of Pulmonary
Hypertension in Sickle Cell Disease Committee (2), we would like to
clarify several points. PH associated with chronic hemolysis has been
moved to Group V in the 2013 classiﬁcation based on: 1) different
histopathology and lower pulmonary vascular resistance (PVR)
compared with other pulmonary arterial hypertension (PAH) sub-
groups; and 2) no proven response to PAH-speciﬁc medications.
